Skip to main content
Fig. 6 | Clinical Proteomics

Fig. 6

From: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection

Fig. 6

AML cell line model sensitivity to ATM inhibition in combination with FLT3 inhibitor. Bliss synergy analysis of combined sensitivity of AML cell line models to sorafenib and KU-60019, A FLT3-ITD/D835Y, B FLT3-ITD/D835V, and C FLT3-ITD (< 0 = antagonistic, > 0 < 10 = additive, > 10 = synergistic). Cell survival comparison of D FLT3-ITD/D835Y, and E FLT3-ITD/D835V cell lines at 62 nM sorafenib in combination with 1.25 µM, 2.5 µM and 5 µM KU-60019 (n = 3 independent replicates, statistical significance calculated via one-way ANOVA *p < 0.05, **p < 0.01 and ***p < 0.001)

Back to article page

Clinical Proteomics

ISSN: 1559-0275